Medical Devices DECODED
Previous edition: 11 Apr 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Signati kicks off trial investigating quicker vasectomy device
Signati aims to take the next big step in vasectomies by offering men a safer and quicker option for family planning.
Signati Medical has enrolled the first patient in a clinical trial investigating its device designed to quicken vasectomy procedures.
The trial, operating under an investigative device exemption from the US Food and Drug Administration (FDA) granted in December 2023, will assess the efficacy and safety of Signati’s Separo device for vasectomies.
A vasectomy is a surgical procedure that cuts and seals each part of vas deferens, the tubes that carry sperm from the epididymis.
Signati states its device can significantly reduce procedure time and offer a minimally invasive approach. Separo can seal each vas deferens in four seconds, according to the US company.
The study’s principal investigator Dr Matthew Mutter alluded to the stagnant nature of the vasectomy space, saying that Signati’s work is the “first major advancement in vasectomy technology in over 40 years.”
Reduced risk of bleeding and faster recovery are amongst the other benefits of the new approach, which Signati calls a Sealed Vasectomy Procedure (SVP). The procedure involves only sealing the tubes as opposed to traditional techniques that include cutting. The system comprises a radiofrequency generator, a handpiece, and clamping forceps. The energy cauterises a part of each vas deferens so that it is permanently separated, with the ends sealed.
Amid increasing restrictions imposed on women seeking abortion in the US, Dr Mutter says Signati’s work could help shift the paradigm of birth control – giving men more responsibility in family planning by offering couples more options.
The number of vasectomies being performed has already risen significantly in the wake of Roe versus Wade.
Whilst there is a lack of data to estimate the market size of the male birth control device market, the global market for women’s sterilisation devices – which includes tubal clips and rings – was estimated to be worth $40m in 2023, according to analysis by GlobalData.
Signati’s CEO William Prentice said: “While highly effective, the traditional vasectomy procedure can be time-consuming and create anxiety for patients. The Signati Separo can potentially transform vasectomies into a faster, more streamlined experience.”
Latest news
Roche secures CE mark for companion diagnostic for cancer therapy Enhertu
Roche’s Ventana test can be used to identify metastatic breast cancer patients that could be eligible to receive Daiichi Sankyo and AstraZeneca’s cancer therapy, Enhertu.
Telehealth clinical trial cuts hospital cardiac readmissions by 76%
The TELE-ACS designed to test SHL Telemedicine’s SmartHeart system was also able to significant drop emergency hospital visits by 41%.
TCAI implements pulsed field ablation system for atrial fibrillation
The system is designed to treat patients with atrial fibrillation, a common heart arrhythmia.
Springing into allergy season: the allergy IgE test landscape
According to GlobalData, there are currently 58 marketed IgE allergy blood IVD tests, 20 in the pipeline, and two active clinical trials.
11th Annual Clinical Trials in Oncology West Coast 2024
The upcoming Clinical Trials In Oncology West Coast 2024 will bring together pharma and biotech experts to discuss clinical-stage cancer therapy development.
In our previous edition
Medical Devices Decoded
US federal court issues decree barring Philips from ventilator industry
10 Apr 2024
Medical Devices Decoded
Boston Scientific initiates study for PFA catheter system
09 Apr 2024
Medical Devices Decoded
J&J seeks cardiovascular market growth with $13.1bn Shockwave deal
08 Apr 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Banking & Payments
Medical Devices
Technology
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer